Afatinib (Gitarel) Phase III clinical trial results and data interpretation

Afatinib (Afatinib) is an irreversible ErbB family receptor tyrosine kinase inhibitor, mainly used to treat patients with non-small cell lung cancer (NSCLC) with EGFR gene mutations. III phase clinical research mainly includes LUX-Lung 3, LUX-Lung 6 and LUX-Lung 7 and other pivotal trials. These studies were designed to evaluate the efficacy and safety of afatinib compared with first-line chemotherapy (eg, pemetrexed plus cisplatin) or first-generation EGFR-TKIs (eg, gefitinib). All patients enrolled in the trial were locally advanced or metastatic NSCLC patients with confirmed EGFR sensitive mutations (exon 19 deletion or L858R mutation).

LUX-Lung 3The study showed that the progression-free survival (PFS) of the afatinib group was significantly better than that of the chemotherapy group, with the median PFS being 11.1 months vs 6.9 months (HR=0.58, P<0.001); objective response rate (ORR) was also higher, reaching 56%, compared with only 23% in the chemotherapy group. The results of the LUX-Lung 6 trial in mainly Asian populations were similar, with median PFS being 11.0 months vs 5.6months (HR=0.28, P<0.001). Together, these two studies established afatinib as the standard of care for first-line treatment of EGFR mutated advanced NSCLC.

LUX-Lung 7This is the first first-line Phase III study to directly compare afatinib with gefitinib. The results showed that afatinib performed better on key efficacy indicators: the median PFS was 11.0 months vs. 10.9months, hazard ratioHR=0.73 (P=0.017), and objective response rate 70% vs 56%. In addition, the disease control rate (DCR) and duration of durable response were both longer in the afatinib group. Although there was no statistically significant difference in overall survival (OS) between the two groups, afatinib showed a more sustained tumor suppression effect, especially in patients with EGFR 19 exon deletion.

Based on the results of multiple III studies, afatinib has demonstrated superior anti-tumor activity and durable efficacy, and is especially suitable for patients with advanced NSCLC with EGFRclassic mutations. Its irreversible inhibition mechanism can act on EGFR, HER2 and HER4 receptors at the same time, reducing the occurrence of drug-resistant mutations. However, adverse reactions of afatinib (such as diarrhea, rash, stomatitis, etc.) are also common and need to be controlled through dose adjustment and supportive care during treatment. Overall, the Phase III trial confirmed the clinical value of afatinib in the first-line treatment of EGFR-mutated lung cancer, laying a solid foundation for precise targeted therapy.

Reference materials:https://www.drugs.com/